HBSP (USA)
-
Managing a Security Response to the Ebola Epidemic in Liberia (Epilogue)
Bourdeaux, Margaret; Kayyem, JulietteCase HBS-KS1309-EOn August 19, 2014, Liberia President Ellen Johnson Sirleaf was faced with an agonizing decision: should she quarantine a densely populated township of Monrovia to halt the spread of the Ebola virus disease? The disease had been ravaging the Republic of Liberia for months but until now, had been isolated in the countryside. Now, the deadly virus was spreading, unchecked, and threatened the 1 million inhabitants of Monrovia, the capital city of th...Starting at €8.20
-
Managing a Security Response to the Ebola Epidemic in Liberia (B)
Bourdeaux, Margaret; Kayyem, JulietteCase HBS-KS1310-EOn August 19, 2014, Liberia President Ellen Johnson Sirleaf was faced with an agonizing decision: should she quarantine a densely populated township of Monrovia to halt the spread of the Ebola virus disease? The disease had been ravaging the Republic of Liberia for months but until now, had been isolated in the countryside. Now, the deadly virus was spreading, unchecked, and threatened the 1 million inhabitants of Monrovia, the capital city of th...Starting at €5.74
-
Managing a Security Response to the Ebola Epidemic in Liberia (A)
Bourdeaux, Margaret; Kayyem, JulietteCase HBS-KS1308-EOn August 19, 2014, Liberia President Ellen Johnson Sirleaf was faced with an agonizing decision: should she quarantine a densely populated township of Monrovia to halt the spread of the Ebola virus disease? The disease had been ravaging the Republic of Liberia for months but until now, had been isolated in the countryside. Now, the deadly virus was spreading, unchecked, and threatened the 1 million inhabitants of Monrovia, the capital city of th...Starting at €8.20
-
Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem (Abridged)
Shih, WillyCase HBS-620071-EService and Operations ManagementThis case describes the efforts of the Bill & Melinda Gates Foundation to lower the cost of production of vaccines to prevent polio infections. It is an abridged version of Case No. 620-021 with less emphasis on comparison between traditional and the new compact modular process developed with the Foundation's funding. It focuses more on the lowering of entry barriers to vaccine manufacture and some of the perceived risks associated with that.Starting at €8.20